secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2023-04-21T23:59:59+00:00
Accession:  0001824293-23-000073
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 8.01, 2.01, 3.03, 4.01, 5.01, 5.02, 5.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vallon Pharmaceuticals completes reverse merger with GRI Bio; combined entity renamed GRI Bio, Inc.
--------------------------------------------------------------------------------

- Merger closed April 21, 2023; former GRI stockholders own ~85% of combined company, Vallon stockholders ~15%.
- Vallon effected 1-for-30 reverse stock split; ticker changes from VLON to GRI on April 24, 2023.
- New board appointed: W. Marc Hertz as CEO, David Szekeres as Chair; prior directors except David Baker resigned.
- EisnerAmper dismissed as auditor; Sadler, Gibb & Associates engaged for fiscal year 2023.
- GRI issued Exchange Warrants for 421,589 shares at $14.73; Equity Warrants to be issued May 8, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/val-20230421.htm
  HTML page:      https://secwatch.observer/filing/0001824293-23-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer